The Association of Autoimmune Diseases with Type 1 Diabetes Mellitus in Children Depends Also by the Length of Partial Clinical Remission Phase (Honeymoon)
Authors:
Open Access
- 4 January 2020
- journal article
- research article
- Published by Wiley in International Journal of Endocrinology
- Vol. 2020, 1-5
Abstract
Type 1 diabetes mellitus (DM) is characterized by irreversible, autoimmune, pancreatic β-cell destruction. During the disease, some patients experience a phase of Partial Clinical Remission (PCR) known as “honeymoon.” This is a transitory period that is characterized by insulin production by residual β cells following DM diagnosis and initiating the insulin therapy. In this study, we aimed to evaluate the influence of insulin production on immune system after the onset of diabetes, and we showed that the duration of honeymoon period could be related to the onset of other autoimmune conditions. For this retrospective study, 159 children aged between 11 and 18 years with type 1 DM were eligible. They have been diagnosed diabetes at least 10 years ago and use exogenous insulin. Our results showed that younger age at the onset of Type 1 DM in children, predicts Celiac Disease. Female sex and low HCO3 levels at the onset of DM had a high predictive value on patients who did not experience longer Partial Clinical Remission phase. Patients with higher BMI at the diagnosis of DM experienced shorter honeymoon period than the average. Smaller of our patients who diagnosed just DM have more than 297 days honeymoon period with respect to patients with one associated autoimmune disease. This may be due to a continuous and prolonged stimulation of immune system during the period of honeymoon that predispose the patient to develop other TH1 diseases. The patients who experienced more than 297 days Partial Clinical Remission seem under risk of developing one other autoimmune disease more than the patients who experienced less than 297 days Partial Clinical Remission. We have to consider that this observation is very intriguing because many protocols spring-up to try prolonging the honeymoon period in patients with autoimmune DM. If this aim is important from a metabolic point of view, long follow-ups are needed to be sure that the risk of other autoimmune diseases does not increase.Keywords
This publication has 10 references indexed in Scilit:
- The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno‐metabolic mechanismsDiabetes/Metabolism Research and Reviews, 2019
- A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetesPLOS ONE, 2017
- Partial clinical remission in type 1 diabetes: a comparison of the accuracy of total daily dose of insulin of <0.3 units/kg/day to the gold standard insulin-dose adjusted hemoglobin A1c of ≤9 for the detection of partial clinical remissionJournal of Pediatric Endocrinology and Metabolism, 2017
- Characteristics and Determinants of Partial Remission in Children with Type 1 Diabetes Using the Insulin-Dose-Adjusted A1C DefinitionJournal of Diabetes Research, 2014
- New Definition for the Partial Remission Period in Children and Adolescents With Type 1 DiabetesDiabetes Care, 2009
- 'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factorsPediatric Diabetes, 2006
- Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?Diabetologia, 2005
- Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre studyDiabetes Research and Clinical Practice, 2005
- Younger Age at Onset and Sex Predict Celiac Disease in Children and Adolescents With Type 1 DiabetesDiabetes Care, 2004
- [Use of cyclosporin A for remission induction in newly-detected insulin-dependent diabetes].1994